Intermediate-risk AML | Adverse-risk AML | |||
---|---|---|---|---|
CPX-351 (n = 40) | 7 + 3 (n = 41) | CPX-351 (n = 99) | 7 + 3 (n = 100) | |
Median age (range), years | 69 (61, 75) | 68 (60, 75) | 68 (60, 75) | 68 (60, 75) |
Age subgroup, n (%) | ||||
60 to 69 years | 25 (63) | 26 (63) | 62 (63) | 65 (65) |
70 to 75 years | 15 (38) | 15 (37) | 37 (37) | 35 (35) |
Male, n (%) | 29 (73) | 25 (61) | 57 (58) | 63 (63) |
ECOG performance status, n (%) | ||||
0 | 11 (28) | 14 (34) | 20 (20) | 29 (29) |
1 | 25 (63) | 23 (56) | 70 (71) | 57 (57) |
2 | 4 (10) | 4 (10) | 9 (9) | 14 (14) |
AML subtype, n (%) | ||||
t-AML | 9 (23) | 3 (7) | 17 (17) | 27 (27) |
AML with antecedent MDS | ||||
With prior HMAs | 19 (48) | 19 (46) | 29 (29) | 32 (32) |
Without prior HMAs | 6 (15) | 12 (29) | 12 (12) | 6 (6) |
AML with antecedent CMML | 2 (5) | 4 (10) | 7 (7) | 6 (6) |
de novo AML with MDS karyotype | 4 (10) | 3 (7) | 34 (34) | 29 (29) |
NCCN cytogenetic risk, n (%) | ||||
n | 39 | 37 | 92 | 97 |
Better risk | 0 | 1 (3) | 0 | 0 |
Intermediate risk | 31 (79) | 31 (84) | 30 (33) | 26 (27) |
Poor risk | 8 (21) | 5 (14) | 62 (67) | 71 (73) |
TP53 mutation, n (%) | – | – | 24 (24) | 31 (31) |
WBC count, n (%) | ||||
n | 40 | 40 | 99 | 100 |
< 20,000/µL | 33 (83) | 35 (88) | 87 (88) | 83 (83) |
≥ 20,000/µL | 7 (18) | 5 (13) | 12 (12) | 17 (17) |
Platelet count, n (%) | ||||
n | 40 | 40 | 99 | 99 |
≤ 50,000/µL | 20 (50) | 21 (53) | 66 (67) | 62 (63) |
> 50,000/µL | 20 (50) | 19 (48) | 33 (33) | 37 (37) |
Median bone marrow blasts (range)a, % | 36 (5, 80) | 35 (6, 88) | 35 (5, 93) | 35 (3, 97) |
Bone marrow blasts, n (%) | ||||
n | 38 | 40 | 97 | 97 |
< 20% | 5 (13) | 4 (10) | 15 (15) | 18 (19) |
20% to 40% | 14 (37) | 19 (48) | 42 (43) | 41 (42) |
> 40% to 60% | 10 (26) | 10 (25) | 20 (21) | 18 (19) |
> 60% | 9 (24) | 7 (18) | 20 (21) | 20 (21) |